Nicolas Soldermann

Effective “activated PI3Kδ syndrome”–targeted therapy with the PI3Kδ inhibitor leniolisib

V. Koneti Rao, Sharon Webster, Virgil A. S. H. Dalm et al. · Blood · 2017 · 286 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

Direct and selective pharmacological disruption of the YAP–TEAD interface by IAG933 inhibits Hippo-dependent and RAS–MAPK-altered cancers

Emilie A. Chapeau, Laurent Sansregret, Giorgio Giacomo Galli et al. · Nature Cancer · 2024 · 132 citations · Full text

Medicine, Cancer Biology, Oncology +15

Discovery of CDZ173 (Leniolisib), Representing a Structurally Novel Class of PI3K Delta-Selective Inhibitors

Klemens Hoegenauer, Nicolas Soldermann, Frédéric J. Zécri et al. · ACS Medicinal Chemistry Letters · 2017 · 118 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Discovery and Pharmacological Characterization of Novel Quinazoline-Based PI3K Delta-Selective Inhibitors

Klemens Hoegenauer, Nicolas Soldermann, Frédéric Stauffer et al. · ACS Medicinal Chemistry Letters · 2016 · 66 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +14

Origins of Boat or Chair Preferences in the Ireland−Claisen Rearrangements of Cyclohexenyl Esters:  A Theoretical Study

Mahmood M. Khaledy, M. Yashar S. Kalani, Kelli S. Khuong et al. · The Journal of Organic Chemistry · 2002 · 45 citations

Natural Sciences, Chemistry, Computational Chemistry +9